JPWO2020188348A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020188348A5 JPWO2020188348A5 JP2021556481A JP2021556481A JPWO2020188348A5 JP WO2020188348 A5 JPWO2020188348 A5 JP WO2020188348A5 JP 2021556481 A JP2021556481 A JP 2021556481A JP 2021556481 A JP2021556481 A JP 2021556481A JP WO2020188348 A5 JPWO2020188348 A5 JP WO2020188348A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- polynucleotide
- modified
- chain
- host cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819988P | 2019-03-18 | 2019-03-18 | |
| US62/819,988 | 2019-03-18 | ||
| PCT/IB2020/000140 WO2020188348A2 (en) | 2019-03-18 | 2020-03-17 | A2/ny-eso-1 specific t cell receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022525925A JP2022525925A (ja) | 2022-05-20 |
| JPWO2020188348A5 true JPWO2020188348A5 (zh) | 2023-03-17 |
Family
ID=70465122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556481A Pending JP2022525925A (ja) | 2019-03-18 | 2020-03-17 | Ａ２／ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220152109A1 (zh) |
| EP (1) | EP3941939A2 (zh) |
| JP (1) | JP2022525925A (zh) |
| CN (1) | CN113906140A (zh) |
| AU (1) | AU2020243431A1 (zh) |
| CA (1) | CA3134102A1 (zh) |
| WO (1) | WO2020188348A2 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3182445A1 (en) | 2020-06-11 | 2021-12-16 | Francisco Leon | Methods and compositions for preventing type 1 diabetes |
| CN116420076A (zh) * | 2020-09-27 | 2023-07-11 | 基因泰克公司 | 高通量多参数免疫细胞接合物筛选测定 |
| US20240207319A1 (en) | 2021-05-06 | 2024-06-27 | Ludwig Institute For Cancer Research Ltd | Compositions and methods for immunotherapy |
| EP4374872A1 (en) * | 2022-11-22 | 2024-05-29 | Koninklijke Philips N.V. | Pde enhanced car-t cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000078334A1 (en) | 1999-06-17 | 2000-12-28 | University Of Maryland Biotechnology Institute | Chimeric chemokine-antigen polypeptides and uses therefor |
| PL208712B1 (pl) | 2001-08-31 | 2011-05-31 | Avidex Ltd | Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd |
| AU2006236439B2 (en) | 2005-04-15 | 2012-05-03 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| WO2008039818A2 (en) * | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| AU2008304555A1 (en) * | 2007-09-25 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| CN114836385A (zh) * | 2014-10-31 | 2022-08-02 | 宾夕法尼亚大学董事会 | 改变cart细胞中的基因表达及其用途 |
| WO2017087723A1 (en) * | 2015-11-19 | 2017-05-26 | The Regents Of The University Of California | Conditionally repressible immune cell receptors and methods of use thereof |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201616238D0 (en) | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
| CN108456247A (zh) * | 2017-02-20 | 2018-08-28 | 上海恒润达生生物科技有限公司 | 靶向ny-eso-1的t细胞受体及其用途 |
-
2020
- 2020-03-17 AU AU2020243431A patent/AU2020243431A1/en active Pending
- 2020-03-17 CA CA3134102A patent/CA3134102A1/en active Pending
- 2020-03-17 US US17/440,136 patent/US20220152109A1/en active Pending
- 2020-03-17 CN CN202080031738.8A patent/CN113906140A/zh active Pending
- 2020-03-17 EP EP20721721.7A patent/EP3941939A2/en active Pending
- 2020-03-17 JP JP2021556481A patent/JP2022525925A/ja active Pending
- 2020-03-17 WO PCT/IB2020/000140 patent/WO2020188348A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7093385B2 (ja) | 薬物制御による導入遺伝子の発現 | |
| You et al. | Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells | |
| Redeker et al. | Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination | |
| Dudley et al. | Adoptive cell transfer therapy | |
| JP6850528B2 (ja) | 二重特異性キメラ抗原受容体およびその治療的使用 | |
| Maher | Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells | |
| JP6985934B2 (ja) | 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用 | |
| Essand et al. | Genetically engineered T cells for the treatment of cancer | |
| US20230210905A1 (en) | T cell-antigen coupler with various construct optimizations | |
| JP7404279B2 (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| EA027153B1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
| KR20160122188A (ko) | 3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도 | |
| CN109575143B (zh) | 双特异性cd20-cd19-car及其应用 | |
| WO2016149665A1 (en) | Her2/erbb2 chimeric antigen receptor | |
| WO2018145648A1 (zh) | 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定 | |
| Yang et al. | Adoptive cellular therapy (ACT) for cancer treatment | |
| JP2021501567A (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞−抗原カプラおよびその方法ならびに使用 | |
| WO2018199595A1 (ko) | 4-1bbl 변이체 및 이를 포함하는 융합 단백질 | |
| WO2023083192A1 (zh) | 联合表达CCR2b和CD40L的工程化免疫细胞及其制备和应用 | |
| WO2018121679A1 (zh) | 表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途 | |
| Moscarelli et al. | The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells | |
| CN115702927A (zh) | 一种广谱性肿瘤疫苗增效的组合物 | |
| JP7564369B2 (ja) | がん及び自己免疫疾患及び炎症性疾患を治療する方法 | |
| US20210087249A1 (en) | Antibody-interferon fusion proteins for enhancing adoptive t cell therapies for the treatment of cancer | |
| Hege et al. | T-cell gene therapy |